score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.261						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (26%)		MEL-IPI_Pat165		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat165		
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Nonsense	p.S988*	0.0962	52.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0				POLE p.S988* (Nonsense)		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	MEL-IPI_Pat165-Normal-SM-5VWIP
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Splice Site		0.3	30.0	0.0	0.0																Investigate Actionability	0.0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				RUNX1  (Splice Site)		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	MEL-IPI_Pat165-Normal-SM-5VWIP
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E775*	0.7619	21.0	0.0	0.0																					0				NF1 p.E775* (Nonsense)		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	MEL-IPI_Pat165-Normal-SM-5VWIP
Biologically Relevant				Copy Number	NF1	Deletion				0.0	0.0																					0				NF1 Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																					0				ATM Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																					0				CHEK1 Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Copy Number	RAD51B	Deletion				0.0	0.0																					0				RAD51B Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Copy Number	MLH3	Deletion				0.0	0.0																					0				MLH3 Deletion		MEL-IPI_Pat165	MEL-IPI_Pat165-Tumor-SM-7A15F	
Biologically Relevant				Microsatellite Stability	Supporting variants		POLE p.S988* (Nonsense)																									0				Supporting variants: POLE p.S988* (Nonsense)		MEL-IPI_Pat165		
Biologically Relevant				Mutational Signature	COSMIC Signature 18	version 2	0.219																									0				COSMIC Signature (version 2) 18 (22%)		MEL-IPI_Pat165		
